Write your message
Volume 7, Issue 5 (September - October 2022)                   J Obstet Gynecol Cancer Res 2022, 7(5): 362-373 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Aminimoghaddam S, Azh N, Noei Teymoordash S, Ghaffari F. Fertility Preservation in Endometrial Cancer: Current Knowledge and Practice. J Obstet Gynecol Cancer Res 2022; 7 (5) :362-373
URL: http://jogcr.com/article-1-454-en.html
1- Department of Gynecology Oncology, Firoozgar Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran , Aminimoghaddam.s@iums.ac.ir
2- Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
3- Department of Gynecology Oncology, Firoozgar Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran
4- Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
Abstract:   (707 Views)

Uterine cancer affects more than 1.28 million people worldwide; considering current world trends in obesity and aging, a +52.7% growth by 2040 is foreseen. Around 5% of endometrial cancer patients are less than 40 years old, meaning that conventional oncologic approaches would result in fertility loss; thus, it is essential to consult patients regarding their fertility and family planning.
Owing to developments of oncofertility, patients are now able to preserve their fertility and complete their childbearing, drafting from the standard of care in endometrial cancer. Strict criteria should be applied to make sure of selecting patients who benefit most from the fertility preservation approach. Furthermore, careful selection of patients increases the possibility of successful treatment.
Most candidates for fertility preservation have risk factors in common with infertility, including polycystic ovarian syndrome, obesity, increasing of age and irregular menses; therefore, Advanced Reproductive Technology (ART) can improve their chances for pregnancy.
Current applied knowledge towards the fertility preservation approach in patients with endometrial cancer is reviewed in this article.

Full-Text [PDF 605 kb]   (252 Downloads) |   |   Full-Text (HTML)  (127 Views)  
Systematic Review: Review | Subject: Gynecology Oncology
Received: 2021/07/24 | Accepted: 2021/11/28 | Published: 2022/07/7

References
1. Ferlay J CM, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941-53. [DOI:10.1002/ijc.31937] [PMID]
2. Ferlay J EM, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018). Available from: https://gco.iarc.fr/tomorrow, accessed [19 July 2019]. Global Cancer Observatory: Cancer Tomorrow. Lyon, France: International Agency for Research on Cancer. 2019.
3. Aminimoghaddam S, Shahrabi-Farahani M, Mohajeri-Tehrani M, Amiri P, Fereidooni F, Larijani B, et al. Epistatic interaction between adiponectin and survivin gene polymorphisms in endometrial carcinoma. Pathol Res Pract. 2015;211(4):293-7. [DOI:10.1016/j.prp.2014.11.012] [PMID]
4. Arnold M, Pandeya N, Byrnes G, Renehan PAG, Stevens GA, Ezzati PM, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16(1):36-46. [DOI:10.1016/S1470-2045(14)71123-4]
5. Arnold M, Lam F, Ervik M, Soerjomataram I. Cancer and obesity: Global burden of cancer attributable to excess weight. Lyon, France: Int Agency Res Cancer; 2015. Accessed on: July 4, 2017. Available from: Available from: http://gco.iarc.fr/obesity.
6. Tehrani MM, Parvizi M, Moghadam SA, Heshmat R, Shaban Nejad-Khas Z, Golchin M. The prevalence of polycystic ovary syndrome in Iranian women with gestational diabetes: a pilot study. Iran J Diabetes Lipid Disord. 2009;57-63.
7. Zahedi P, Aminimoghaddam S, Sayahpour FA, Haghpanah V, Amiri P, Fereidoni F, et al. Association of survivin gene polymorphism with endometrial cancer. Int J Gynecol Cancer. 2012;22(1):35-7. [DOI:10.1097/IGC.0b013e318229902c] [PMID]
8. Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013. J Natl Cancer Inst. 2018;110(4):354-61. [DOI:10.1093/jnci/djx214] [PMID]
9. Gressel GM, Parkash V, Pal L. Management options and fertility-preserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer. Int J Gynaecol Obstet. 2015;131(3):234-9. [DOI:10.1016/j.ijgo.2015.06.031] [PMID]
10. Tock S, Jadoul P, Squifflet JL, Marbaix E, Baurain JF, Luyckx M. Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature. Front Med (Lausanne). 2018;5:240. [DOI:10.3389/fmed.2018.00240] [PMID] [PMCID]
11. Chan JL, Wang ET. Oncofertility for women with gynecologic malignancies. Gynecol Oncol. 2017;144(3):631-6. [DOI:10.1016/j.ygyno.2016.12.013] [PMID]
12. Obermair A, Baxter E, Brennan DJ, McAlpine JN, Muellerer JJ, Amant F, et al. Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstet Gynecol Sci. 2020;63(4):417-31. [DOI:10.5468/ogs.19169] [PMID] [PMCID]
13. Knez J, Al Mahdawi L, Takač I, Sobočan M. The Perspectives of Fertility Preservation in Women with Endometrial Cancer. Cancers. 2021;13(4): 602. [DOI:10.3390/cancers13040602] [PMID] [PMCID]
14. Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, et al. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol. 2014;134(2):385-92. https://doi.org/10.1016/j.ygyno.2014.06.003 [DOI:10.1016/j.ygyno.2014.05.018]
15. Holman DA. Fertility Preservation in Gynecologic Cancer. Semin Oncol Nurs. 2019;35(2):202-10. [DOI:10.1016/j.soncn.2019.02.007] [PMID]
16. McKenzie ND, Kennard JA, Ahmad S. Fertility preserving options for gynecologic malignancies: A review of current understanding and future directions. Crit Rev Oncol Hematol. 2018;132:116-24. [DOI:10.1016/j.critrevonc.2018.09.020] [PMID]
17. Ghaoomi M, Aminimoghaddam S, Safari H, Mahmoudzadeh A. Awareness and practice of cervical cancer and Pap smear testing in a teaching hospital in Tehran. Tehran Univ Med J. 2016;74:183-9.
18. Carneiro MM, Lamaita RM, Ferreira MC, Silva-Filho AL. Fertility-preservation in endometrial cancer: is it safe? Review of the literature. JBRA Assist Reprod. 2016;20(4):232-9. [DOI:10.5935/1518-0557.20160045] [PMID] [PMCID]
19. Corzo C, Santillan N, Westin S, Ramirez P. Updates on Conservative Management of Endometrial Cancer. J Minim Invasive Gynecol. 2017;25. [DOI:10.1016/j.jmig.2017.07.022] [PMID]
20. Kistner RW. Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium. Cancer. 1959;12:1106-22. https://doi.org/10.1002/1097-0142(195911/12)12:6<1106::AID-CNCR2820120607>3.0.CO;2-M [DOI:10.1002/1097-0142(195911/12)12:63.0.CO;2-M]
21. Aminimoghaddam S, Norouzi S. Ovarian failure due to cancer treatment and fertility preservation options. Tehran Univ Med J. 2016;74:1-8.
22. Burnett AF, Quick C, Huffman LB, Savage JE, Zorn KK. Should ovaries be conserved in low-risk endometrial cancer? Gynecol Oncol. 2018;149:150-1. [DOI:10.1016/j.ygyno.2018.04.344]
23. Jia P, Zhang Y. Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer. Oncotarget. 2017;8(35):59940-9. [DOI:10.18632/oncotarget.18404] [PMID] [PMCID]
24. Lee TS, Lee JY, Kim JW, Oh S, Seong SJ, Lee JM, et al. Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: a Korean Gynecologic Oncology Group study. Gynecol Oncol. 2013;131(2):289-93. [DOI:10.1016/j.ygyno.2013.08.024] [PMID]
25. La Rosa VL, Shah M, Kahramanoglu I, Cerentini TM, Ciebiera M, Lin L-T, et al. Quality of life and fertility preservation counseling for women with gynecological cancer: an integrated psychological and clinical perspective. J Psychosom Obstet Gynaeco. 2020;41(2):86-92. [DOI:10.1080/0167482X.2019.1648424] [PMID]
26. Kim MJ, Choe SA, Kim MK, Yun BS, Seong SJ, Kim YS. Outcomes of in vitro fertilization cycles following fertility-sparing treatment in stage IA endometrial cancer. Arch Gynecol Obstet. 2019;300(4):975-80. [DOI:10.1007/s00404-019-05237-2] [PMID]
27. Schuring AN, Fehm T, Behringer K, Goeckenjan M, Wimberger P, Henes M, et al. Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation. Arch Gynecol Obstet. 2018;297(1):241-55. [DOI:10.1007/s00404-017-4594-3] [PMID] [PMCID]
28. Patil M, Mahajan N. Fertility preservation in endometrial carcinoma: Case series of 11 patients. Onco Fertil J. 2018;1(1):36-43. [DOI:10.4103/tofj.tofj_10_18]
29. Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril. 2013;99(6):1476-84. [DOI:10.1016/j.fertnstert.2013.03.029] [PMID]
30. Taylan E, Oktay K. Fertility preservation in gynecologic cancers. Gynecol Oncol. 2019. [DOI:10.1016/j.ygyno.2019.09.012] [PMID]
31. Chen J, Cheng Y, Fu W, Peng X, Sun X, Chen H, et al. PPOS Protocol Effectively Improves the IVF Outcome Without Increasing the Recurrence Rate in Early Endometrioid Endometrial Cancer and Atypical Endometrial Hyperplasia Patients After Fertility Preserving Treatment. Front Med. 2021;8(1167). [DOI:10.3389/fmed.2021.581927] [PMID] [PMCID]
32. Practice Bulletin No. 149: Endometrial cancer. Obstet Gynecol. 2015;125(4):1006-26. [DOI:10.1097/01.AOG.0000462977.61229.de] [PMID]
33. Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31:12-39. [DOI:10.1136/ijgc-2020-002230] [PMID]
34. Gonthier C, Trefoux-Bourdet A, Koskas M. Impact of Conservative Managements in Young Women With Grade 2 or 3 Endometrial Adenocarcinoma Confined to the Endometrium. Int J Gynecol Cancer. 2017;27(3):493-9. [DOI:10.1097/IGC.0000000000000895] [PMID]
35. Park JY, Kim DY, Kim TJ, Kim JW, Kim JH, Kim YM, et al. Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstet Gynecol. 2013;122(1):7-14. [DOI:10.1097/AOG.0b013e3182964ce3] [PMID]
36. Chae SH, Shim SH, Lee SJ, Lee JY, Kim SN, Kang SB. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer. Int J Gynecol Cancer. 2019;29(1):77-85. [DOI:10.1136/ijgc-2018-000036] [PMID]
37. Koskas M, Yazbeck C, Walker F, Clouqueur E, Agostini A, Ruat S, et al. Fertility-sparing management of grade 2 and 3 endometrial adenocarcinomas. Anticancer Res. 2011;31(9):3047-9.
38. Aminimoghaddam S, Mahmoudzadeh F, Maghsoudnia A, Ghaemmaghami F. Intraoperative visualization, frozen section, and permanent pathology in endometrial cancer. Tehran Univ Med J. 2014;72:617-22.
39. Yang B, Xu Y, Zhu Q, Xie L, Shan W, Ning C, et al. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecol Oncol. 2019;153(1):55-62. [DOI:10.1016/j.ygyno.2019.01.014] [PMID]
40. Ruiz MP, Huang Y, Hou JY, Tergas AI, Burke WM, Ananth CV, et al. All-cause mortality in young women with endometrial cancer receiving progesterone therapy. Am J Obstet Gynecol. 2017;217(6):669.e1-.e13. [DOI:10.1016/j.ajog.2017.08.007] [PMID] [PMCID]
41. Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000;89(8):1765-72. https://doi.org/10.1002/1097-0142(20001015)89:8<1765::AID-CNCR17>3.0.CO;2-F [DOI:10.1002/1097-0142(20001015)89:83.0.CO;2-F]
42. Kim MK, Seong SJ, Song T, Kim ML, Yoon BS, Jun HS, et al. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer. Gynecol Oncol. 2013;130(3):470-3. [DOI:10.1016/j.ygyno.2013.06.035] [PMID]
43. Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol. 2011;205(2):103-10. [DOI:10.1016/j.ajog.2011.01.025] [PMID] [PMCID]
44. Garzon S, Uccella S, Zorzato PC, Bosco M, Franchi M, Student V, et al. Fertility-sparing management for endometrial cancer: review of literature. Minerva Med. 2021;112(1):55-69. [DOI:10.23736/S0026-4806.20.07072-X] [PMID]
45. Chang YN, Zhang Y, Wang YJ, Wang LP, Duan H. Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis. Fertil Steril. 2011;96(4):957-61. [DOI:10.1016/j.fertnstert.2011.07.1146] [PMID]
46. Mazzon I, Corrado G, Masciullo V, Morricone D, Ferrandina G, Scambia G. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril. 2010;93(4):1286-9. [DOI:10.1016/j.fertnstert.2008.12.009] [PMID]
47. Rodríguez-Trujillo A, Martínez-Serrano MJ, Martínez-Román S, Martí C, Buñesch L, Nicolau C, et al. Preoperative Assessment of Myometrial Invasion in Endometrial Cancer by 3D Ultrasound and Diffusion-Weighted Magnetic Resonance Imaging: A Comparative Study. Int J Gynecol Cancer. 2016;26(6):1105-10. [DOI:10.1097/IGC.0000000000000724] [PMID]
48. Savelli L, Ceccarini M, Ludovisi M, Fruscella E, De Iaco PA, Salizzoni E, et al. Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging. Ultrasound Obstet Gynecol. 2008;31(5):560-6. [DOI:10.1002/uog.5295] [PMID]
49. Falcone F, Laurelli G, Losito S, Di Napoli M, Granata V, Greggi S. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol. 2017;28(1):e2. [DOI:10.3802/jgo.2017.28.e2] [PMID] [PMCID]
50. Eriksson LSE, Lindqvist PG, Flöter Rådestad A, Dueholm M, Fischerova D, Franchi D, et al. Transvaginal ultrasound assessment of myometrial and cervical stromal invasion in women with endometrial cancer: interobserver reproducibility among ultrasound experts and gynecologists. Ultrasound Obstet Gynecol. 2015;45(4):476-82. [DOI:10.1002/uog.14645] [PMID]
51. Kalogera E, Dowdy SC, Bakkum-Gamez JN. Preserving fertility in young patients with endometrial cancer: current perspectives. Int J Womens Health. 2014;6:691-701. [DOI:10.2147/IJWH.S47232] [PMID] [PMCID]
52. Song T, Seong SJ, Bae D-S, Suh DH, Kim D-Y, Lee K-H, et al. Synchronous primary cancers of the endometrium and ovary in young women: A Korean Gynecologic Oncology Group Study. Gynecol Oncol. 2013;131(3):624-8. [DOI:10.1016/j.ygyno.2013.09.009] [PMID]
53. Zhang Q, Qi G, Kanis MJ, Dong R, Cui B, Yang X, et al. Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia. Oncotarget. 2017;8(34):57642-53. [DOI:10.18632/oncotarget.17588] [PMID] [PMCID]
54. Network NCC. uterine neoplasm. NCCN guidelines for patients: uterine neoplasms Version 32021 [Internet]. 2021. Available from: [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1473]
55. Sundar S, Balega J, Crosbie E, Drake A, Edmondson R, Fotopoulou C, et al. BGCS uterine cancer guidelines: Recommendations for practice. Eur J Obstet Gynecol Reprod Biol. 2017;213:71-97. [DOI:10.1016/j.ejogrb.2017.04.015] [PMID]
56. Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol. 2005;106(4):693-9. [DOI:10.1097/01.AOG.0000172423.64995.6f] [PMID]
57. Arendas K, Aldossary M, Cipolla A, Leader A, Leyland NA. Hysteroscopic resection in the management of early-stage endometrial cancer: report of 2 cases and review of the literature. J Minim Invasive Gynecol. 2015;22(1):34-9. [DOI:10.1016/j.jmig.2014.08.782] [PMID]
58. Cade TJ, Quinn MA, Rome RM, Neesham D. Progestogen treatment options for early endometrial cancer. Bjog. 2010;117(7):879-84. [DOI:10.1111/j.1471-0528.2010.02552.x] [PMID]
59. He Y, Wang Y, Zhou R, Wang J. Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer. Int J Gynecol Cancer. 2020;30(12):1902-07. [DOI:10.1136/ijgc-2020-001570] [PMID]
60. Falcone F, Maggiore ULR, Di Donato V, Perrone AM, Frigerio L, Bifulco G, et al. Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study. J Gynecol Oncol. 2020;31(5). [DOI:10.3802/jgo.2020.31.e74] [PMID] [PMCID]
61. Rosas P, Valzacchi GR, Viglierchio VT. Conservative Treatment for Endometrial Hyperplasia with Atypia and Grade 1 Endometrioid Endometrial Cancer. J Minim Invasive Gynecol. 2020;27(7):S104. [DOI:10.1016/j.jmig.2020.08.146]
62. Terzic M, Norton M, Terzic S, Bapayeva G, Aimagambetova G. Fertility preservation in endometrial cancer patients: options, challenges and perspectives. Ecancermedicalscience. 2020;14:1030. [DOI:10.3332/ecancer.2020.1030] [PMID] [PMCID]
63. Koskas M, Uzan J, Luton D, Rouzier R, Daraï E. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril. 2014;101(3):785-94. [DOI:10.1016/j.fertnstert.2013.11.028] [PMID]
64. Karimi-Zarchi M, Dehghani-Firoozabadi R, Tabatabaie A, Dehghani-Firoozabadi Z, Teimoori S, Chiti Z, et al. A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation. Clin Exp Obstet Gynecol. 2013;40(3):421-4.
65. Fan Z, Li H, Hu R, Liu Y, Liu X, Gu L. Fertility-preserving treatment in young women with grade 1 presumed stage IA endometrial adenocarcinoma: a meta-analysis. Int J Gynecol Cancer. 2018;28(2):385-93. [DOI:10.1097/IGC.0000000000001164] [PMID]
66. Atallah D, El Kassis N, Safi J, El Hachem H, Chahine G, Moubarak M. The use of hysteroscopic endometrectomy in the conservative treatment of early endometrial cancer and atypical hyperplasia in fertile women. Arch Gynecol Obstet. 2021:1-7. [DOI:10.1007/s00404-021-06048-0] [PMID]
67. Zhang Z, Huang H, Feng F, Wang J, Cheng N. A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer. J Gynecol Oncol. 2019;30(4):e61. [DOI:10.3802/jgo.2019.30.e61] [PMID] [PMCID]
68. Fan Z, Li H, Hu R, Liu Y, Liu X, Gu L. Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis. Int J Gynecol Cancer. 2018;28(2):385-93. [DOI:10.1097/IGC.0000000000001164] [PMID]
69. Acosta-Torres S, Murdock T, Matsuno R, Beavis AL, Stone RL, Wethington SL, et al. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates. Gynecol Oncol. 2020;157(2):348-56. [DOI:10.1016/j.ygyno.2020.02.008] [PMID]
70. Sadidi H, Izadi-Mood N, Sarmadi S, Yarandi F, Amini-Moghaddam S, Esfahani F, et al. Comparison of clinicopathologic variables in coexistence cancers of the endometrium and ovary: A review of 55 cases in an academic center in Iran. J Res Med Sci. 2015;20(8):727-32. [DOI:10.4103/1735-1995.168315] [PMID] [PMCID]
71. Li J, Zhu Q, Yang B, Ning C, Liu X, Luo X, et al. Risk factors for ovarian involvement in young and premenopausal endometrioid endometrial cancer patients. Eur J Obstet Gynecol Reprod Biol. 2018;222:151-4. [DOI:10.1016/j.ejogrb.2018.01.030] [PMID]
72. Lee TS, Kim JW, Kim TJ, Cho CH, Ryu SY, Ryu HS, et al. Ovarian preservation during the surgical treatment of early stage endometrial cancer: a nation-wide study conducted by the Korean Gynecologic Oncology Group. Gynecol Oncol. 2009;115(1):26-31. https://doi.org/10.1016/j.ygyno.2009.06.041 [DOI:10.1016/j.ygyno.2004.11.051] [PMID]
73. Ashrafganjoei T, Bahman A, Noei Teymoordash S, Aminimoghaddam S, Ebrahimi A, Talayeh M. The Incidence of Ovarian Involvement in Endometrioid Endometrial Adenocarcinoma: A Retrospective Analysis. J Obstet Gynecol Cancer Res. 2021;6(3):105-9. [DOI:10.30699/jogcr.6.3.105]
74. Li AJ, Giuntoli RL, 2nd, Drake R, Byun SY, Rojas F, Barbuto D, et al. Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol. 2005;106(6):1304-8. [DOI:10.1097/01.AOG.0000185511.91694.1e] [PMID]
75. Jing Y-X, Zhang L-L, Li H-X, Yue F, Wang N, Xue S-L, et al. Fertility preservation in cancer patients. Reprod Dev Med. 2021;5(1):44-54. [DOI:10.4103/2096-2924.309789]
76. Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405-10. [DOI:10.1016/S0140-6736(04)17222-X]
77. Anderson RA, Wallace WH, Baird DT. Ovarian cryopreservation for fertility preservation: indications and outcomes. Reproduction. 2008;136(6):681-9. [DOI:10.1530/REP-08-0097] [PMID]
78. von Wolff M, Germeyer A, Liebenthron J, Korell M, Nawroth F. Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part II: fertility preservation techniques. Arch Gynecol Obstet. 2018;297(1):257-67. [DOI:10.1007/s00404-017-4595-2] [PMID] [PMCID]
79. Bralo H, Roethlisberger M, Nouri K. Fertility preservation in women with endometrial cancer. memo - Memo. 2020;13(4):421-5. [DOI:10.1007/s12254-020-00661-6]
80. Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207(4):266.e1-12. [DOI:10.1016/j.ajog.2012.08.011] [PMID]
81. Wang L, Luo X, Wang Q, Lv Q, Wu P, Liu W, et al. Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome. J Gynecol Oncol. 2021;32(5). [DOI:10.3802/jgo.2021.32.e70] [PMID] [PMCID]
82. Harada M, Osuga Y. Does polycystic ovary syndrome independently affect oncologic and reproductive outcomes in patients with endometrial cancer receiving fertility-sparing treatment? J Gynecol Oncol. 2021;32(5):e80. [DOI:10.3802/jgo.2021.32.e80] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2022 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.